Free delivery on orders over €40
Free delivery on orders over €40
Illustration d’un œil et des nutriments associés à la formule AREDS 2
AREDS 2 Compléments alimentaires DMLA Lutéine

AREDS 2 Formula: Ingredients, Doses and Who It Is For

Written by the Phytocea team Reviewed by Phytocea Scientific Advisory Board Editorial credit: Dr. Arnaud BERNARD
• • 8 min
Summarize with AI:

Written by Dr. Arnaud BERNARD and reviewed by the Phytocea Scientific Committee. Labels checked on 2 October 2026.

Key takeaways

  • The AREDS 2 formula combines six nutrients: vitamin C, vitamin E, zinc, copper, lutein and zeaxanthin.
  • The pairing of 10 mg lutein + 2 mg zeaxanthin does not, by itself, constitute the full formula.
  • The trials studied people with intermediate AMD or advanced AMD in one eye, not the general population.
  • Adding EPA and DHA did not improve the primary AREDS2 outcome.
  • Many eye supplements sold in France are inspired by AREDS2 without reproducing every dose.

AREDS 2 is a nutritional formula studied in people at high risk of progression of age-related macular degeneration. It combines vitamin C 500 mg, vitamin E 400 IU, zinc 80 mg, copper 2 mg, lutein 10 mg and zeaxanthin 2 mg (1, 2). It is not a formula intended indiscriminately for every adult.

What is AREDS 2?

AREDS stands for Age-Related Eye Disease Study. Funded by the US National Eye Institute, these trials assessed combinations of vitamins, carotenoids and minerals in participants monitored for AMD or cataracts.

AREDS2 included 4,203 participants aged 50 to 85. All had bilateral intermediate AMD or advanced AMD in one eye. The aim was not to test a general multivitamin or study eye strain related to screen use.

The first AREDS study observed an approximately 25% reduction in the risk of progression to advanced AMD among high-risk categories receiving the antioxidant-zinc combination (1). AREDS2 studied the addition of lutein/zeaxanthin and EPA/DHA, as well as the removal of beta-carotene and a lower dose of zinc (2).

What is the complete AREDS 2 formula?

ComponentDaily dose studiedRole in the formula
Vitamin C500 mgWater-soluble antioxidant
Vitamin E400 IUFat-soluble antioxidant
Lutein10 mgMacular pigment carotenoid
Zeaxanthin2 mgMacular pigment carotenoid
Zinc80 mg of zinc as zinc oxide; a 25 mg variant was studiedMineral used in the AREDS formula
Copper2 mg of copper as cupric oxideAdded alongside the high zinc dose

The table shows the doses used in the US trial. It is not a recommendation for self-supplementation. For comparison, the European nutrient reference value for zinc is 10 mg per day. The AREDS dose of 80 mg is eight times higher. Vitamin E at 400 IU is also far above the amount in a typical nutritional formula. These quantities require professional oversight.

AREDS 1 and AREDS 2: what changed?

Point comparedAREDSAREDS2
CarotenoidBeta-carotene 15 mgLutein 10 mg + zeaxanthin 2 mg tested as a replacement
Zinc80 mg80 mg compared with 25 mg
Omega-3sNot studied in the formulaDHA 350 mg + EPA 650 mg tested
PopulationSeveral AMD categoriesParticipants at high risk of progression

The most useful change concerns beta-carotene. In AREDS2, lutein and zeaxanthin provided a replacement without the lung-risk signal observed with beta-carotene in former smokers (2, 3). Ten-year follow-up reinforced this substitution (3).

The comparison of 80 mg with 25 mg of zinc found no statistically significant difference in the primary outcome. Commercial formulas in Europe often use lower doses than the US study formula.

Which profiles did the studies examine?

The AREDS and AREDS2 findings mainly apply to people with intermediate AMD or advanced AMD in one eye. The studies did not show comparable benefit in people without AMD or with early AMD characterised by only a few small drusen (9, 11).

Age alone cannot determine the decision. Two 65-year-olds may have completely different circumstances based on their retinal examinations. The stage observed by an ophthalmologist—not a general “senior vision” promise—determines whether a high-dose formula is relevant.

There is another clear limitation: the trials did not show an effect of the formula on cataracts (11). AREDS2 should not be used as a generic argument for every age-related eye concern.

This distinction changes how you read a label. “Inspired by AREDS2” does not mean that the product was tested in young adults, for screen-related eye strain or for dry eyes. It means only that some ingredients or doses come from that body of literature.

To put your own profile in context, read our page on the different stages of AMD and ask your ophthalmologist for advice.

Omega-3s, lutein and zeaxanthin: what did the trial actually compare?

AREDS2 used a factorial design. In addition to the base formula, participants received lutein/zeaxanthin, EPA/DHA, both combinations or a placebo. Adding EPA/DHA did not further reduce progression to advanced AMD in the primary outcome (2).

Lutein and zeaxanthin also produced no significant difference from placebo in the primary analysis. Secondary analyses nevertheless supported replacing beta-carotene with them, particularly among participants with the lowest dietary carotenoid intake and former smokers (2, 3).

To distinguish the 10/2 ratio from the complete formula and understand dietary sources, see our guide to lutein and zeaxanthin dosage.

DHA has a separate European claim: at 250 mg per day, it contributes to the maintenance of normal vision. This claim does not make DHA a required component of an AREDS2 formula.

How can you identify an AREDS 2 formula on a label?

  1. Find the daily serving: one, two or four capsules.
  2. Record the six amounts separately.
  3. Check for 10 mg of lutein and 2 mg of zeaxanthin.
  4. Compare vitamin C with 500 mg and vitamin E with 400 IU.
  5. Record the zinc dose and form.
  6. Check for copper alongside a high zinc dose.
  7. Classify the formula as complete, partial or different.

Example: one capsule contains 5 mg of lutein and the directions state two capsules. The daily dose is therefore 10 mg. If the same formula provides zinc 15 mg, vitamin C 180 mg and vitamin E 30 mg, it uses several AREDS2 components but not the complete trial doses.

To apply this method to any brand, use our guide to reading an eye supplement label.

Do eye supplements sold in France reproduce the full formula?

We reviewed the ten labels in Phytocea's comparison. The table below does not judge their overall quality. It measures only how closely their published daily doses match the six AREDS2 components.

ProductLutein / zeaxanthinComparison with AREDS2
ORetine10 mg / 2 mgPartial: all six nutrient families present, with lower doses of C, E and zinc
Nutrof Total10 mg / 2 mgPartial: all six nutrient families present, with lower antioxidant and zinc doses
PreserVision 310 mg / 2 mgPartial: European adaptation with DHA
Macula-Z10 mg / 2 mgPartial: lower doses of C, E and zinc
Suvéal Duo10 mg / 2 mgPartial: DHA included, different doses
Ocufolin Forte10 mg / 2 mgDifferent: focused on folates, B vitamins and NAC
Visioplex10 mg / not disclosedDifferent: botanical formula with no separately stated zeaxanthin
Ocuvite Lutéine Forte6 mg / 0.5 mgPartial at lower doses
VisioptylNot disclosedCannot be classified from public data
Difrarel 1000 mg / 0 mgDifferent: medicine containing bilberry and beta-carotene

Method: manufacturer formulas and directions checked on 2 October 2026. “Partial” means that at least one dose differs from the research formula; it is not an overall judgement of the product.

Prices and use profiles appear in our 2026 comparison of eye formulas.

AREDS 2 and ORetine: two different scopes

For two capsules, ORetine provides lutein 10 mg, zeaxanthin 2 mg, vitamin C 160 mg, d-alpha-tocopherol 30 mg or 45 IU, zinc 11 mg and copper 1.56 mg. It adds astaxanthin 2 mg, reduced glutathione 60 mg, OPCs 28.5 mg, bilberry, selenium, manganese, and vitamins B and D.

This composition includes the six AREDS2 nutrient families, but not the trial's high doses of vitamin C, vitamin E and zinc. ORetine is therefore a multi-ingredient eye formula inspired by this literature, not a complete copy of the US formula. It costs €29.90 for 60 capsules, or 30 days at the stated serving.

See ORetine's complete formula.

When should you seek professional advice?

A high-dose AREDS2 formula should be chosen with an ophthalmologist. Ask for advice before taking one if you smoke or used to smoke, take any medication, use several supplements or have kidney disease.

This article is for informational purposes only and is not a substitute for professional medical advice. A rapid loss of vision, distorted lines, a fixed spot or flashes of light require prompt assessment. Before taking a supplement, consult a qualified healthcare professional if you are pregnant, breastfeeding, taking any medication or using several products containing zinc, copper or vitamin E.

Research and references

(1) Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol. 2001;119(10):1417-1436. doi:10.1001/archopht.119.10.1417

(2) Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005-2015. doi:10.1001/jama.2013.4997

(3) Chew EY, Clemons TE, Agrón E, et al. Long-term outcomes of adding lutein/zeaxanthin and omega-3 fatty acids to the AREDS supplements on age-related macular degeneration progression. JAMA Ophthalmol. 2022;140(7):692-698. doi:10.1001/jamaophthalmol.2022.1640

(4) Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2017;7:CD000254. doi:10.1002/14651858.CD000254.pub4

(5) AREDS2 Research Group. The Age-Related Eye Disease Study 2: study design and baseline characteristics. Ophthalmology. 2012;119(11):2282-2289. doi:10.1016/j.ophtha.2012.05.027

(6) Bernstein PS, Li B, Vachali PP, et al. Lutein, zeaxanthin, and meso-zeaxanthin: the basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease. Prog Retin Eye Res. 2016;50:34-66. doi:10.1016/j.preteyeres.2015.10.003

(7) Li LH, Lee JC, Leung HH, Lam WC, Fu Z, Lo ACY. Lutein supplementation for eye diseases. Nutrients. 2020;12(6):1721. doi:10.3390/nu12061721

(8) Chew EY, Clemons TE, Agrón E, et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology. 2013;120(8):1604-1611.e4. doi:10.1016/j.ophtha.2013.01.021

(9) Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev. 2017;7:CD000253. doi:10.1002/14651858.CD000253.pub4

(10) EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on the substantiation of health claims related to docosahexaenoic acid. EFSA Journal. 2010;8(10):1734. doi:10.2903/j.efsa.2010.1734

(11) National Eye Institute. AREDS/AREDS2 Clinical Trials: major findings, studied populations and formula compositions. Accessed 2 October 2026.

(12) Haute Autorité de santé. Age-related macular degeneration: diagnostic and therapeutic management. Clinical practice guideline.

Back to Health issues

To go further

Top 10 Best Eye Supplements in 2026

Written by Dr. Arnaud BERNARD and reviewed by the Phytocea Scientific Committee. Product information checked on 21 September 2026. Key takeaways The...

How to Choose an Eye Supplement: 6 Precise Criteria

Written by Dr. Arnaud BERNARD and reviewed by the Phytocea Scientific Committee. Updated on 21 September 2026. Key takeaways Always read the...

Lutein for Eye Health: Dosage, Sources and Clinical Data

Lutein is a carotenoid pigment essential for the functioning of the retina. It can be found in food, but its supplementation has...

What is AMD?

What is AMD? Age-related macular degeneration (AMD) is an eye disease, specifically affecting the retina. This is a degradation of the macula*....